Elevai Labs, Inc. Common Stock

NASDAQ:ELAB

$2.05 USD

-$0.36 (-14.94%)

Volume
678.92K
Average Volume
695.95K
Market Capitalization
$6.3M
P/E Ratio
-8.31
Dividend Yield
0.00%
Price Target
$
Year High
$778.00
Year Low
$2.05
Payout Ratio
$0.00
Current Ratio
$3.86

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Mr. Graydon Bensler C.F.A.
Industry Biotechnology
Sector Healthcare
Current Symbol ELAB
CUSIP None
CIK 0001840563
Web None
Phone None
Currency USD
Employees 18
Country US

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 3.86
Quick Ratio 3.40
Cash Ratio 3.02

Sales & Book Value

Annual Sales $1.71M
Price / Sales 2.58
Cash Flow -0.27
Price / Cash Flow -1.04
Price / Book 5.31

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.4
Trailing P/E Ratio -8.31
PEG Ratio 1.12
P/E Growth 1.12
Net Income $-4.3M
Net Margin -223.57%
Pretax Margin -223.57%
Return on Equity -124.94%
Return on Assets -48.81%

Financials Score

AltmanZ Score -0.49
Piotroski Score 2.00
Working Capital 6.1M
Total Assets 11.21M
Ebit -4.64M
Market Cap 6.3M
Total Liabilities 2.65M

Poll Results

About Elevai Labs, Inc. Common Stock (NASDAQ:ELAB) Stock

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California. ...

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

2024-11-22 18:23:00

NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (Elevai" or the "Company") announced today it will implement a 1-for-200 reverse stock split (“Reverse Stock Split”) of its common stock, which will be effective at midnight on November 27, 2024.

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

2024-11-22 17:00:00

NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has withdrawn the previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), as a result of notice from the Depositary Trust Company (“DTC”) that due to logistical issues, DTC would not be able to accept the tenders of Common Stock.

CORRECTION - Elevai Labs Inc.

2024-11-14 14:35:00

NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc. (NASDAQ: ELAB), please note that in the headline and first paragraph, the financial results are from the company's third fiscal quarter of 2024, not the second fiscal quarter as previously stated; as such, the header over the first bullet list should note the financial results as being from the three and nine months ended September 30, 2024, rather than the three and six months ended June 30, 2024 as previous stated.

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

2024-11-14 09:08:00

Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation. Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation.

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

2024-11-04 17:45:00

NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock.

Frequently Asked Questions

What is the current Elevai Labs, Inc. Common Stock (ELAB) stock price?

Elevai Labs, Inc. Common Stock(NASDAQ:ELAB) stock price is $2.05 in the last trading session. During the trading session, ELAB stock reached the peak price of $778.0 while $2.045 was the lowest point it dropped to. The percentage change in ELAB stock occurred in the recent session was --14.94% while the dollar amount for the price change in ELAB stock was -$-0.36.

ELAB's industry and sector of operation?

The NASDAQ listed ELAB is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ELAB?

Mr. Graydon Bensler C.F.A. | Chief Executive Officer, Chief Financial Officer, Secretary & Director
|
|
|
|

How many employees does ELAB have?

Number of ELAB employees currently stands at 18. ELAB operates from None, None, None None, US.

Link for ELAB official website?

Official Website of ELAB is: None

How do I contact ELAB?

ELAB could be contacted at phone #None and can also be accessed through its website. ELAB operates from None, None, None None, US.

How many shares of ELAB are traded daily?

The average number of ELAB shares traded daily for last 3 months was 695.95K.

What is the market cap of ELAB currently?

The market value of ELAB currently stands at $6.3M with its latest stock price at $2.05